CD8A and neoplasm: Another study targeting FABP5 showed that inhibition of the protein promoted iron death in tumor cells, upregulated CD80 and CD86 expression, and activated CD8+ T-cells [80], suggesting the feasibility of restoring immunotherapy sensitivity by regulating lipid metabolism.